TG Therapeutics announces commercial launch of BRIUMVI

TG Therapeutics announced the commercial launch of BRIUMVI, for the treatment of relapsing forms of multiple sclerosis, RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is the first and only anti-CD20 monoclonal antibody approved for patients with RMS that can be administered in a one-hour infusion following the starting dose. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, "Our team has been working hard to make BRIUMVI available as quickly as possible, and we are pleased to announce that BRIUMVI is now available to healthcare providers and patients." Mr. Weiss continued, "We continue to be highly focused on ensuring patients who can benefit from BRIUMVI can easily access treatment. We have built what we consider to be a best-in-class team to support this launch, as well as a robust patient support program designed to aid in accessing BRIUMVI at all points through the treatment journey. We encourage those interested to visit www.briumivi.com to learn more and also find the full prescribing information."